Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis
Clin Exp Rheumatol
.
2023 Mar;41(2):402-403.
doi: 10.55563/clinexprheumatol/7k9ajj.
Epub 2023 Mar 1.
Authors
Maria Vincenza Mastrolia
#
1
,
Sara I Orsini
#
2
,
Edoardo Marrani
3
,
Ilaria Maccora
3
,
Ilaria Pagnini
3
,
Gabriele Simonini
4
Affiliations
1
Rheumatology Unit, Meyer Children's University Hospital, Florence, Italy. maria.mastrolia@unifi.it.
2
Department of Woman, Child and of General and Specialised Surgery, University of Campania Luigi Vanvitelli, Naples, Italy.
3
Rheumatology Unit, Meyer Children's University Hospital, Florence, Italy.
4
Neurofarba Department, University of Florence, Italy.
#
Contributed equally.
PMID:
36861743
DOI:
10.55563/clinexprheumatol/7k9ajj
No abstract available
Publication types
Letter
MeSH terms
Azetidines* / therapeutic use
Calcinosis*
Dermatomyositis* / complications
Dermatomyositis* / drug therapy
Humans
Janus Kinase Inhibitors* / therapeutic use
Substances
baricitinib
Janus Kinase Inhibitors
Azetidines